ClinicalTrials.gg
RecruitingNCT07411547FATUS-OLDUpdated Jun 25, 2026

Clinical Relevance of Ultrasound-based Intramuscular Fat Infiltration Assessment in Hospitalized Older Adults (FATUS-OLD)

An observational study in Physical Performance Decline in Older Adults, Sarcopenia and Muscle Fat Infiltration, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Nantes University Hospital · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
115
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Sarcopenia with a site in France — 23 open to participants now, 24 under way, none of them phase 3. Sarcopenia · France.

Planned enrollment
9th of 25
115 · median 72
Started
2026
with 5 others
Observational
25 of 78
5 open now
Primary completion
2028-11
later than 18 of 23 live
Registered
74th of 78
by date
Lead sponsor
3 of 78
Nantes University Hospital

Among the 78 studies in Sarcopenia with a site in France, this one is the 9th largest by planned enrollment of the 25 observational ones that give a count, is one of 6 that started in 2026, is one of 25 observational ones, reaches primary completion later than 18 of the 23 other live ones, and was the 74th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

23 of the 78 studies in Sarcopenia with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Sarcopenia with a site in France, or all of them as a file.
02

Study summary

Sarcopenia in older adults is associated not only with loss of muscle mass but also with deterioration of muscle quality, particularly intramuscular fat infiltration. While muscle mass is commonly assessed, muscle quality remains insufficiently explored in routine clinical practice.

The FATUS-OLD study aims to evaluate the clinical relevance of a novel ultrasound-based multiparametric approach to assess intramuscular fat infiltration and muscle volume in hospitalized older adults undergoing rehabilitation. The main hypothesis is that higher intramuscular fat infiltration at baseline is associated with poorer recovery of physical performance at 6 months, independently of muscle volume.

This non-invasive, rapid, and radiation-free imaging approach could improve sarcopenia phenotyping and help identify new prognostic biomarkers for clinical follow-up and future interventional trials.

Read the detailed description

FATUS-OLD is a prospective, monocentric, open-label, non-randomized observational study conducted at Nantes University Hospital. The study includes older adults aged 75 years and older hospitalized in a rehabilitation day-hospital program for gait or balance disorders.

Participants undergo ultrasound assessments of skeletal muscle using a CE-marked ultrasound device capable of measuring muscle volume and intramuscular fat infiltration through matrix-based analysis. Measurements are performed at baseline and during follow-up.

The primary objective is to assess the prognostic value of baseline intramuscular fat infiltration on physical performance recovery at 6 months, evaluated using the Short Physical Performance Battery (SPPB). Secondary objectives include the relationship between muscle volume, muscle quality, muscle strength, appendicular lean mass measured by bioelectrical impedance analysis, and clinically significant events such as falls, loss of independence, rehospitalization, and mortality.

The study is exploratory and aims to validate innovative ultrasound-derived biomarkers of muscle quality in a real-life geriatric population.

03

Conditions studied

  • Physical Performance Decline in Older Adults
  • Sarcopenia
  • Muscle Fat Infiltration

Browse trials for

Keywords

  • Sarcopenia
  • Older adults
  • Muscle quality
  • Intramuscular fat
  • Ultrasound imaging
  • Physical performance
  • Geriatric rehabilitation
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All participants undergo standardized clinical assessments and ultrasound-based muscle evaluations as part of routine rehabilitation follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 75 years
  • Hospitalized in rehabilitation day-hospital program
  • Written

Exclusion criteria

Exclusion Criteria:

  • Moderate to severe neurocognitive disorders
  • Inability to comply with study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
115 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational cohort

    All participants undergo standardized clinical assessments and ultrasound-based muscle evaluations as part of routine rehabilitation follow-up.

06

What researchers measure

Primary outcomes

  1. Change in Short Physical Performance Battery (SPPB) score

    Difference between SPPB score at baseline and at 6 months, used to evaluate recovery of physical performance in relation to baseline intramuscular fat infiltration.

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Association between muscle volume and appendicular lean mass

    Correlation between ultrasound-derived muscle volume (with and without correction for intramuscular fat infiltration) and appendicular lean mass measured by bioelectrical impedance analysis.

    Time frame: Baseline

  2. Association between muscle volume and muscle strength

    Relationship between muscle volume and maximal muscle strength for corresponding muscle groups, with and without correction for intramuscular fat infiltration.

    Time frame: Baseline and 6 months

  3. Occurrence of clinically significant events

    Incidence of falls, loss of independence, rehospitalization, cognitive decline, institutionalization, and mortality.

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2028, 30 months after the start.

Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 30 months is above that.

Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
May 21, 2026
Primary completionEst.
Nov 21, 2028
CompletionEst.
Nov 21, 2028
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07411547
Collaborators
AGENCE NATIONALE DE RECHERCHE
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
May 21, 2026
Primary completion
Nov 21, 2028 (estimated)
Completion
Nov 21, 2028 (estimated)
Last update
Jun 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion